{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:22:11Z","timestamp":1768342931478,"version":"3.49.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.amjms.2021.09.008","type":"journal-article","created":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T06:53:51Z","timestamp":1633157631000},"page":"444-451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunosuppressive Treatments for Idiopathic Membranous Nephropathy: A Pilot Study According to Histopathological Stages"],"prefix":"10.1016","volume":"363","author":[{"given":"Zhipeng","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaosi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2021.09.008_bib0001","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000348638","article-title":"Changing spectrum of biopsy-proven primary glomerular diseases over the past 15 years: a single-center study in China","volume":"181","author":"Pan","year":"2013","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.amjms.2021.09.008_bib0002","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1681\/ASN.2016010093","article-title":"Long-term exposure to air pollution and increased risk of membranous nephropathy in China","volume":"27","author":"Xu","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2021.09.008_bib0003","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0270-9295(03)00049-4","article-title":"Diagnosis and natural course of membranous nephropathy","volume":"23","author":"Glassock","year":"2003","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.amjms.2021.09.008_bib0004","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2021.09.008_bib0005","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004293.pub3","article-title":"Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome","author":"Chen","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.amjms.2021.09.008_bib0006","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2021.09.008_bib0007","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1517\/14656566.2010.494599","article-title":"Management of idiopathic membranous nephropathy","volume":"11","author":"Ponticelli","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.amjms.2021.09.008_bib0008","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MAJ.0b013e3181ca3a7d","article-title":"Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial","volume":"339","author":"Chen","year":"2010","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.amjms.2021.09.008_bib0009","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/nep.12569","article-title":"Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial","volume":"21","author":"Ramachandran","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.amjms.2021.09.008_bib0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12882-018-1011-5","article-title":"Clinical implications of pathological features of primary membranous nephropathy","volume":"19","author":"Zhang","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.amjms.2021.09.008_bib0011","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2021.09.008_bib0012","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00281-014-0423-y","article-title":"Immunopathogenesis of membranous nephropathy: an update","volume":"36","author":"Debiec","year":"2014","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.amjms.2021.09.008_bib0013","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.kint.2016.09.048","article-title":"Membranous nephropathy: integrating basic science into improved clinical management","volume":"91","author":"Cattran","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2021.09.008_bib0014","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.autrev.2015.10.004","article-title":"Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN)","volume":"15","author":"Radice","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.amjms.2021.09.008_bib0015","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1053\/j.ajkd.2015.07.006","article-title":"AJKD Atlas of renal pathology: membranous nephropathy","volume":"66","author":"Fogo","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjms.2021.09.008_bib0016","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2217\/bmm-2017-0081","article-title":"A comprehensive narrative review of diagnostic biomarkers in human primary membranous nephropathy","volume":"11","author":"Kalantari","year":"2017","journal-title":"Biomark Med"},{"key":"10.1016\/j.amjms.2021.09.008_bib0017","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962921003360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962921003360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:40:45Z","timestamp":1757702445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962921003360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0002962921003360"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2021.09.008","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppressive Treatments for Idiopathic Membranous Nephropathy: A Pilot Study According to Histopathological Stages","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2021.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}